Nobody Noticed Gland Pharma's Profit Nearly Doubled This Quarter -- They Should Have

Result season in India produces so many earnings releases every week that genuinely exceptional numbers occasionally get lost in the noise. Gland Pharma's Q4 FY26 results are a case study in exactly that — a pharmaceutical company that nearly doubled its profit, posted its highest-ever operating margin, and received barely a fraction of the coverage that went to larger IT and banking names.

Gland Pharma delivered its strongest performance yet in Q4 FY26, reporting record revenues and sharply higher profitability. The injectable-focused pharmaceutical major posted a 22% year-on-year jump in quarterly revenue and a 97% surge in adjusted profit after tax, underscoring robust growth across its core and CDMO businesses.

The margin story is equally striking. EBITDA grew 48% year-on-year in Q4, with margins expanding to 29.43% — the highest quarterly level in recent history. The board also recommended a final dividend of ₹20 per share.

The number that deserves the most attention, however, is not the profit — it is what is driving it. The CDMO segment remained a key growth engine, contributing 46% of revenues in Q4 and growing 36% year-on-year. For the full year FY26, CDMO revenue grew 28%, reinforcing its strategic importance to the company's future. CDMO — Contract Development and Manufacturing Organisations — is the business of making drugs for other pharmaceutical companies. It is high-margin, long-tenure, and structurally growing as global pharma majors seek to outsource manufacturing to cost-efficient, quality-certified Indian players.

The management has expressed confidence in achieving a 15% CAGR over the next four years, supported by a healthy product pipeline and capacity expansion. New product launches like Dalbavancin — a specialty injectable antibiotic — are already contributing to revenue diversification.

Revenue from the USA aggregated to ₹980.7 crore, up 25.44% year-on-year. Europe revenue added up to ₹381.4 crore, up 36% year-on-year. India revenue grew 28% year-on-year to ₹67 crore. The geographic spread of this growth matters — it is not a single-market story.

Domestic institutional investors have been steadily increasing their stake, with mutual fund holdings rising from 30.19% in September 2025 to 31.78% in March 2026. This 159-basis-point increase over two quarters signals growing domestic institutional confidence in the company's prospects, with 25 mutual fund schemes now holding the stock.

The stock rose over 16% on results day — the week's biggest volume shocker, trading at 16.1 times its prior one-month average — and then quietly faded from the news cycle within 48 hours. For a company guiding 15% CAGR for four years, with CDMO revenues growing at nearly double that rate, the Gland Pharma story is one that deserved more than a single day of attention.

Disclaimer: The information provided in this article is intended solely for general informational purposes. It does not constitute financial, investment, legal, or tax advice, nor should it be interpreted as a recommendation or endorsement of any investment strategy or financial product. Readers are advised to consult with a licensed financial advisor or other qualified professionals before making any financial decisions.